GDC-0570

GDC-0570 is a novel, potent, selective, orally active pan-PIM inhibitor. GDC-0570 demonstrates synergistic antitumor efficacy when combined with Sotorasib (HY-114277) in acquired KRASis-resistant NSCLC[1].

Product Specifications

CAS Number

[1586041-58-8]

Product Name Alternative

NB004

UNSPSC

12352005

Target

Pim

Related Pathways

JAK/STAT Signaling

Field of Research

Cancer

Smiles

O=C(C1=CSC(C2=C(C=CC=C2F)F)=N1)NC3=C([C@@H]4CC[C@H]([C@@H](CO4)F)N)N(N=C3)C

Molecular Formula

C20H20F3N5O2S

Molecular Weight

451.47

References & Citations

[1]Fu S, et al. Abstract CT116: Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors[J]. Cancer Research, 2024, 84 (7_Supplement) : CT116-CT116.